GlassScriptPhysician profile
Ashish S Chogle
NPI 1023273141
$2,393.42
in general payments reported to CMS, 2019-2025
18 companies · $249 in 2025
The $249 reported for 2025 was more than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $1,061 · 2021: $52.92 · 2022: $52.58 · 2023: $566 · 2024: $201 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,008 · Education: $8.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,007.53 |
| Education | $8.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuraxis, INC. | $1,155.21 | 2020-2023 | |
| Mirum Pharmaceuticals, INC. | $214.99 | 2023-2025 | Livmarli |
| Abbvie INC. | $178.07 | 2019-2023 | Linzess |
| Travere Therapeutics, INC. | $128.89 | 2019-2023 | Cholbam |
| Genzyme Corporation | $125.00 | 2023 | |
| Fresenius Kabi USA, LLC | $121.61 | 2023 | Smoflipid |
| Qol Medical, LLC | $90.57 | 2024-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $84.18 | 2023 | Linzess |
| Nestle Healthcare Nutrition INC. | $72.59 | 2021-2023 | |
| Alcresta Therapeutics, INC. | $43.95 | 2024-2025 | Relizorb |
| Takeda Pharmaceuticals U.S.A., INC. | $30.99 | 2024 | Gattex |
| Albireo Pharma, INC. | $25.83 | 2024 | Bylvay |
| Kyowa Kirin, INC. | $23.52 | 2025 | |
| Aquestive Therapeutics, INC. | $22.01 | 2019 | |
| Tolmar, INC. | $21.85 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rhythm Pharmaceuticals, INC. | $20.67 | 2025 | Imcivree |
| Olympus America INC. | $20.26 | 2024 | Endoclot Phs |
| Concordia Pharmaceuticals INC. | $13.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Chogle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.